Shin Nippon Biomedical Laboratories (FRA:YB3) Piotroski F-Score: 5 (As of Jun. 28, 2026) — Near Median


FRA:YB3 Shin Nippon Biomedical Laboratories Ltd FRA:YB3
74 GF Score
Price €6.00
GF Value €9.47
! 5 Warning Signs
View Full Analysis

What is Shin Nippon Biomedical Laboratories Piotroski F-Score?

Shin Nippon Biomedical Laboratories FRA:YB3 +1.69% 74 Piotroski F-Score is 5 as of Jun. 28, 2026, which is at its 10-year median of 5.00. GuruFocus rates FRA:YB3 with a GF Score™ of 74/100 and a GF Value™ of €9.47. The stock has 5 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, Shin Nippon Biomedical Laboratories ranks better than 64.76% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shin Nippon Biomedical Laboratories has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Shin Nippon Biomedical Laboratories's Piotroski F-Score or its related term are showing as below:

FRA:YB3' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 5   Max: 7
Current: 5

During the past 13 years, the highest Piotroski F-Score of Shin Nippon Biomedical Laboratories was 7. The lowest was 4. And the median was 5.

Shin Nippon Biomedical Laboratories  (FRA:YB3) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Shin Nippon Biomedical Laboratories Piotroski F-Score Related Terms


Shin Nippon Biomedical Laboratories Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Shin Nippon Biomedical Laboratories's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shin Nippon Biomedical Laboratories Piotroski F-Score Chart

Shin Nippon Biomedical Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 4.00 5.00 5.00 5.00

Shin Nippon Biomedical Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 0.00 0.00 0.00 5.00

FRA:YB3 vs TMO, DHR, IDXX: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shin Nippon Biomedical Laboratories Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Shin Nippon Biomedical Laboratories's Piotroski F-Score falls into.


FRA:YB3
74GF Score
Shin Nippon Biomedical Laboratories Ltd FRA:YB3
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was €24.9 Mil.
Cash Flow from Operations was €45.4 Mil.
Revenue was €177.3 Mil.
Gross Profit was €88.5 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (573.505 + 572.671) / 2 = €573.088 Mil.
Total Assets at the begining of this year (Mar25) was €573.5 Mil.
Long-Term Debt & Capital Lease Obligation was €117.7 Mil.
Total Current Assets was €234.3 Mil.
Total Current Liabilities was €214.4 Mil.
Net Income was €30.6 Mil.

Revenue was €201.1 Mil.
Gross Profit was €105.3 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (468.554 + 573.505) / 2 = €521.0295 Mil.
Total Assets at the begining of last year (Mar24) was €468.6 Mil.
Long-Term Debt & Capital Lease Obligation was €140.8 Mil.
Total Current Assets was €204.4 Mil.
Total Current Liabilities was €181.6 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shin Nippon Biomedical Laboratories's current Net Income (TTM) was 24.9. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shin Nippon Biomedical Laboratories's current Cash Flow from Operations (TTM) was 45.4. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=24.894/573.505
=0.04340677

ROA (Last Year)=Net Income/Total Assets (Mar24)
=30.562/468.554
=0.06522621

Shin Nippon Biomedical Laboratories's return on assets of this year was 0.04340677. Shin Nippon Biomedical Laboratories's return on assets of last year was 0.06522621. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Shin Nippon Biomedical Laboratories's current Net Income (TTM) was 24.9. Shin Nippon Biomedical Laboratories's current Cash Flow from Operations (TTM) was 45.4. ==> 45.4 > 24.9 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=117.685/573.088
=0.20535241

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=140.845/521.0295
=0.27032059

Shin Nippon Biomedical Laboratories's gearing of this year was 0.20535241. Shin Nippon Biomedical Laboratories's gearing of last year was 0.27032059. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=234.337/214.367
=1.093158

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=204.413/181.554
=1.12590744

Shin Nippon Biomedical Laboratories's current ratio of this year was 1.093158. Shin Nippon Biomedical Laboratories's current ratio of last year was 1.12590744. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Shin Nippon Biomedical Laboratories's number of shares in issue this year was 41.631. Shin Nippon Biomedical Laboratories's number of shares in issue last year was 41.631. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=88.52/177.298
=0.49927241

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=105.254/201.149
=0.52326385

Shin Nippon Biomedical Laboratories's gross margin of this year was 0.49927241. Shin Nippon Biomedical Laboratories's gross margin of last year was 0.52326385. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=177.298/573.505
=0.30914813

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=201.149/468.554
=0.42929737

Shin Nippon Biomedical Laboratories's asset turnover of this year was 0.30914813. Shin Nippon Biomedical Laboratories's asset turnover of last year was 0.42929737. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+1+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shin Nippon Biomedical Laboratories has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Shin Nippon Biomedical Laboratories (FRA:YB3) has a Piotroski F-Score of 5 as of Jun. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shin Nippon Biomedical Laboratories and its competitors. This is near median its historical median of 5.00. Over the past decade, Shin Nippon Biomedical Laboratories' Piotroski F-Score has ranged from 4.00 to 7.00. According to the industry distribution chart, Shin Nippon Biomedical Laboratories ranks #74 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 35.2%.
Is Shin Nippon Biomedical Laboratories' Piotroski F-Score too high?
Shin Nippon Biomedical Laboratories' current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Shin Nippon Biomedical Laboratories' value of 5 is 0% at this industry median. Based on the distribution chart, Shin Nippon Biomedical Laboratories ranks #74 out of 210 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shin Nippon Biomedical Laboratories ranks #74 out of 210 companies for Piotroski F-Score. This puts Shin Nippon Biomedical Laboratories in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Shin Nippon Biomedical Laboratories' value of 5 is 0% at this benchmark. Historically, Shin Nippon Biomedical Laboratories' own Piotroski F-Score has ranged from 4.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Shin Nippon Biomedical Laboratories has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shin Nippon Biomedical Laboratories's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shin Nippon Biomedical Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shin Nippon Biomedical Laboratories's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (FRA:YB3) has a current Piotroski F-Score of 5. The stock's GF Value™ is €9.47, compared to a current price of €6.00 — trading 36.6% below its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Medical Diagnostics & Research industry median of 5.00. Shin Nippon Biomedical Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (FRA:YB3), the current Piotroski F-Score is 5 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shin Nippon Biomedical Laboratories (FRA:YB3) Overvalued in 2026?

Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued. The current stock price of €6.00 is trading 36.6% below its estimated GF Value™ of €9.47.

Key valuation signals for FRA:YB3:

  • Piotroski F-Score: 5 (near median its 10-year median of 5.00)
  • GF Value™: €9.47 vs. price of €6.00 (36.6% below fair value)
  • GF Score™: 74/100 with 5 warning signs
  • Industry Position: 0% at the Medical Diagnostics & Research median (#74 of 210)

No single metric tells the full story. See the FRA:YB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shin Nippon Biomedical Laboratories Business Description

Other Exchanges 2395:JapanYB3:Germany
Address 8-1 Akashi-cho, Tokyo, JPN
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
74GF Score

Get the complete analysis for FRA:YB3

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.00
Price
€9.47
GF Value